NCT01756898

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis

A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 370 (actual)
• Sponsor: Daiichi Sankyo · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this research study is to gather scientific information about the effectiveness of the study drug, ASB17061 capsules, when compared to placebo in adult subjects with atopic dermatitis.

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	5 mg ASB17061	Oral administration of 5 mg ASB17061 taken once daily for 28 consecutive days.
DRUG	Placebo	Oral administration of placebo taken once daily for 28 consecutive days.
DRUG	10 mg ASB17061	Oral administration of 10 mg ASB17061 taken once daily for 28 consecutive days.
DRUG	20 mg ASB17061	Oral administration of 20 mg ASB17061 taken once daily for 28 consecutive days.

Timeline

• Start date: 2012-11-28
• Primary completion: 2014-01-14
• Completion: 2014-01-14
• First posted: 2012-12-28
• Last updated: 2021-02-16
• Results posted: 2021-02-16

Locations

40 sites across 1 country: United States